raloxifene

Summary

Summary: A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue.

Top Publications

  1. pmc Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factors
    Peter Collins
    Department of Cardiology, Royal Brompton and Harefield NHS Trust and NHLI, Imperial College London, Sydney Street, London, UK
    Circulation 119:922-30. 2009
  2. pmc American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction
    Kala Visvanathan
    Cancer Policy and Clinical Affairs, 2318 Mill Rd, Suite 800, Alexandria, VA 22314, USA
    J Clin Oncol 27:3235-58. 2009
  3. pmc Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer
    Victor G Vogel
    NSABP, Pittsburgh, PA 15212, USA
    Cancer Prev Res (Phila) 3:696-706. 2010
  4. doi Selective estrogen receptor modulators as brain therapeutic agents
    Maria Angeles Arevalo
    Instituto Cajal, CSIC, Avenida Doctor Arce 37, E 28002 Madrid, Spain
    J Mol Endocrinol 46:R1-9. 2011
  5. ncbi Differential effects of estradiol and raloxifene on collagen biosynthesis in cultured human skin fibroblasts
    Arkadiusz Surazynski
    Department of Medicinal Chemistry, Medical Academy of Bialystok, 15 230 Bialystok, Poland
    Int J Mol Med 12:803-9. 2003
  6. ncbi Selective estrogen receptor modulators decrease reactive astrogliosis in the injured brain: effects of aging and prolonged depletion of ovarian hormones
    George Barreto
    Instituto Cajal, Consejo Superior de Investigaciones Cientificas, Avenida Doctor Arce 37, E 28002 Madrid, Spain
    Endocrinology 150:5010-5. 2009
  7. ncbi Neuroprotective properties of 17beta-estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice
    S Callier
    Oncology and Molecular Endocrinology Research Center, and Faculty of Pharmacy, Laval University, , QC, G1K 7P4, Canada
    Synapse 41:131-8. 2001
  8. pmc Effects of genistein aglycone in osteoporotic, ovariectomized rats: a comparison with alendronate, raloxifene and oestradiol
    A Bitto
    Section of Pharmacology, Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Italy
    Br J Pharmacol 155:896-905. 2008
  9. ncbi Molecular determinants for the tissue specificity of SERMs
    Yongfeng Shang
    Department of Adult Oncology, Dana Farber Cancer Institute, 44 Binney Street, and Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Science 295:2465-8. 2002
  10. ncbi Cognitive function in postmenopausal women treated with raloxifene
    K Yaffe
    Department of Psychiatry, University of California at San Francisco, 94121, USA
    N Engl J Med 344:1207-13. 2001

Research Grants

  1. Effects of herbs on transcription and cell proliferation
    Dale Leitman; Fiscal Year: 2002
  2. Effects of herbs on transcription and cell proliferation
    Dale Leitman; Fiscal Year: 2003
  3. IMMUNOLOGICAL ASPECTS OF HEMORRHAGE
    Irshad Chaudry; Fiscal Year: 2000
  4. IMMUNOLOGICAL ASPECTS OF HEMORRHAGE
    Irshad Chaudry; Fiscal Year: 1999
  5. IMMUNOLOGICAL ASPECTS OF HEMORRHAGE
    Irshad Chaudry; Fiscal Year: 2002
  6. IMMUNOLOGICAL ASPECTS OF HEMORRHAGE
    Irshad Chaudry; Fiscal Year: 2001
  7. IMMUNOLOGICAL ASPECTS OF HEMORRHAGE
    Irshad Chaudry; Fiscal Year: 2000
  8. IMMUNOLOGICAL ASPECTS OF HEMORRHAGE
    Irshad Chaudry; Fiscal Year: 2002
  9. CARDIAC ESTROGEN RECEPTORS AND MI-- MOUSE MODELS
    Richard Karas; Fiscal Year: 2001
  10. CARDIAC ESTROGEN RECEPTORS AND MI-- MOUSE MODELS
    Richard Karas; Fiscal Year: 2002

Detail Information

Publications307 found, 100 shown here

  1. pmc Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factors
    Peter Collins
    Department of Cardiology, Royal Brompton and Harefield NHS Trust and NHLI, Imperial College London, Sydney Street, London, UK
    Circulation 119:922-30. 2009
    The Raloxifene Use for The Heart (RUTH) trial showed that raloxifene, a selective estrogen receptor modulator, had no overall effect on the incidence of coronary events in women with established coronary heart disease or coronary heart ..
  2. pmc American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction
    Kala Visvanathan
    Cancer Policy and Clinical Affairs, 2318 Mill Rd, Suite 800, Alexandria, VA 22314, USA
    J Clin Oncol 27:3235-58. 2009
    ..Vascular and vasomotor events do not persist post-treatment across all ages. In postmenopausal women, raloxifene and tamoxifen reduce the risk of ER-positive invasive BC with equal efficacy...
  3. pmc Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer
    Victor G Vogel
    NSABP, Pittsburgh, PA 15212, USA
    Cancer Prev Res (Phila) 3:696-706. 2010
    ..The FDA approved the SERM raloxifene for breast cancer risk reduction following its demonstrated effectiveness in preventing invasive breast cancer ..
  4. doi Selective estrogen receptor modulators as brain therapeutic agents
    Maria Angeles Arevalo
    Instituto Cajal, CSIC, Avenida Doctor Arce 37, E 28002 Madrid, Spain
    J Mol Endocrinol 46:R1-9. 2011
    ..New SERMs with specific actions on neurons and glial cells may represent promising therapeutic tools for the brain...
  5. ncbi Differential effects of estradiol and raloxifene on collagen biosynthesis in cultured human skin fibroblasts
    Arkadiusz Surazynski
    Department of Medicinal Chemistry, Medical Academy of Bialystok, 15 230 Bialystok, Poland
    Int J Mol Med 12:803-9. 2003
    The dose-dependent effect of a 24 h treatment with estradiol (E(2)) (1, 2, 5, 10 nM) and raloxifene (Rx) (1, 5, 10, 20 microM) on ER alpha and ER beta mRNA expression, collagen bio-synthesis, prolidase activity, MMP-2, MMP-9, insulin-like ..
  6. ncbi Selective estrogen receptor modulators decrease reactive astrogliosis in the injured brain: effects of aging and prolonged depletion of ovarian hormones
    George Barreto
    Instituto Cajal, Consejo Superior de Investigaciones Cientificas, Avenida Doctor Arce 37, E 28002 Madrid, Spain
    Endocrinology 150:5010-5. 2009
    ..In this study we assessed whether raloxifene and tamoxifen, two selective estrogen receptor modulators, have effects similar to estradiol in astrocytes...
  7. ncbi Neuroprotective properties of 17beta-estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice
    S Callier
    Oncology and Molecular Endocrinology Research Center, and Faculty of Pharmacy, Laval University, , QC, G1K 7P4, Canada
    Synapse 41:131-8. 2001
    ..MPTP) induced dopamine depletion in striatum of C57Bl/6 mice by 17beta-estradiol, progesterone, and raloxifene, whereas 17alpha-estradiol had no effect...
  8. pmc Effects of genistein aglycone in osteoporotic, ovariectomized rats: a comparison with alendronate, raloxifene and oestradiol
    A Bitto
    Section of Pharmacology, Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Italy
    Br J Pharmacol 155:896-905. 2008
    ..To clarify this, we investigated the effects of genistein compared with alendronate, raloxifene and oestradiol in an animal model of established osteoporosis.
  9. ncbi Molecular determinants for the tissue specificity of SERMs
    Yongfeng Shang
    Department of Adult Oncology, Dana Farber Cancer Institute, 44 Binney Street, and Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Science 295:2465-8. 2002
    ..The therapeutic effectiveness of SERMs such as tamoxifen and raloxifene in breast cancer depends on their antiestrogenic activity. In the uterus, however, tamoxifen is estrogenic...
  10. ncbi Cognitive function in postmenopausal women treated with raloxifene
    K Yaffe
    Department of Psychiatry, University of California at San Francisco, 94121, USA
    N Engl J Med 344:1207-13. 2001
    ..Whether raloxifene, a selective estrogen-receptor modulator, might have similar actions is not known...
  11. ncbi Difference between genomic actions of estrogen versus raloxifene in human ovarian cancer cell lines
    H Sasaki
    Department of Obstetrics and Gynecology, Osaka University Medical School, Yamadaoka, Suita, Osaka, Japan
    Oncogene 27:2737-45. 2008
    ..The molecular mechanisms of the effects of SERMs such as raloxifene on the tumor progression of epithelial ovarian cancer are also still unclear...
  12. ncbi Patient compliance with alendronate, risedronate and raloxifene for the treatment of osteoporosis in postmenopausal women
    J D Ringe
    Medical Department IV, Hospital Leverkusen, University of Cologne, Leverkusen, Germany
    Curr Med Res Opin 23:2677-87. 2007
    ..The aim was to investigate patient compliance with different osteoporosis medications commonly prescribed in clinical practice, to determine risk factors associated with discontinuation and to evaluate quality of life changes...
  13. ncbi Effects of raloxifene and estradiol on bone turnover parameters in intact and ovariectomized rats
    S Canpolat
    Faculty of Medicine, Department of Physiology, Yeditepe University, Istanbul, Turkey
    J Physiol Biochem 66:23-8. 2010
    This study was designed to investigate effects of raloxifene (RLX) and estradiol on bone formation and resorption in intact and ovariectomized (ovx) rat models...
  14. ncbi Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women
    Janne Komi
    Hormos Medical Corporation, Turku, Finland
    Menopause 12:202-9. 2005
    To compare ospemifene and raloxifene regarding their effects on hormones, lipids, genital tract, and tolerability in postmenopausal women.
  15. ncbi Pharmacokinetics of raloxifene in male Wistar-Hannover rats: influence of complexation with hydroxybutenyl-beta-cyclodextrin
    Michael F Wempe
    Eastman Chemical Company, Kingsport, TN, USA
    Int J Pharm 346:25-37. 2008
    b>Raloxifene is a highly insoluble, highly metabolized serum estrogen receptor modulator approved for use in the treatment of osteoporosis...
  16. ncbi Disposition mechanisms of raloxifene in the human intestinal Caco-2 model
    Eun Ju Jeong
    Department of Pharmaceutical Sciences, College of Pharmacy, Washington State University, Pullman, Washington 99164 6510, USA
    J Pharmacol Exp Ther 310:376-85. 2004
    The purpose of this study was to determine the mechanisms responsible for transport of raloxifene and its hydrophilic conjugates. Human intestinal Caco-2 cell culture model and Caco-2 cell lysate were used for the studies...
  17. ncbi Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention
    Woo Chan Park
    Lynn Sage Breast Cancer Research Program, Robert H Lurie Comprehensive Cancer Center, Olson Pavilion 8258, 303 E Chicago Avenue, Chicago, IL 60611, USA
    Trends Mol Med 8:82-8. 2002
    ..b>Raloxifene, a related SERM, is now available to treat osteoporosis and is also being tested as a preventive for breast ..
  18. ncbi Sulfation of raloxifene and 4-hydroxytamoxifen by human cytosolic sulfotransferases
    Josie L Falany
    Department of Pharmacology and Toxicology, 1670 University Blvd, Volker Hall G133M, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Drug Metab Dispos 34:361-8. 2006
    b>Raloxifene and 4-hydroxytamoxifen (4-OHT) are important estrogen-related drugs used in the treatment of osteoporosis and breast cancer...
  19. ncbi Administration of raloxifene reduces sensorimotor and working memory deficits following traumatic brain injury
    Olga N Kokiko
    Restorative Neuroscience Laboratory, Department of Psychology, Southern Illinois University, Carbondale, IL 62901, USA
    Behav Brain Res 170:233-40. 2006
    ..The present study examined the effects of raloxifene, a SERM, on functional recovery after bilateral cortical contusion injury (bCCI) or sham procedure...
  20. doi Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR)
    Carolyn D Runowicz
    National Surgical Adjuvant Breast and Bowel Project, National Cancer Institute, Pittsburgh, PA, USA
    Am J Obstet Gynecol 205:535.e1-5. 2011
    This study reports the gynecologic conditions in postmenopausal women (intact uterus on enrollment) in the National Surgical Adjuvant Breast and Bowel Project (NSABP) study of tamoxifen and raloxifene (STAR)/P-2 trial.
  21. pmc The effect of tamoxifen and raloxifene on estrogen metabolism and endometrial cancer risk
    Marian Y Williams-Brown
    Department of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, United States
    J Steroid Biochem Mol Biol 126:78-86. 2011
    ..While tamoxifen (TAM) use increases the risk of endometrial hyperplasia and malignancy, raloxifene (RAL) has neutral effects on the uterus...
  22. doi Raloxifene ameliorates detrimental enzymatic and nonenzymatic collagen cross-links and bone strength in rabbits with hyperhomocysteinemia
    M Saito
    Department of Orthopaedic Surgery, Jikei University School of Medicine, Tokyo, Japan
    Osteoporos Int 21:655-66. 2010
    ..Such detrimental cross-link formation in bone was ameliorated by raloxifene (RLX) treatment.
  23. ncbi Cardioprotective effects of long-term treatment with raloxifene, a selective estrogen receptor modulator, on myocardial ischemia/reperfusion injury in ovariectomized rats
    Ming Ting Chung
    Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Chi Mei Medical Center, Tainan
    Menopause 17:127-34. 2010
    The aim of this study was to investigate the beneficial effect of long-term treatment with raloxifene (RAL), a selective estrogen receptor modulator, on myocardial ischemia/reperfusion (MI/R) injury in ovariectomized (Ovx) rats.
  24. ncbi Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance
    Daniel C Kemp
    University of North Carolina, Curriculum of Toxicology, Chapel Hill, North Carolina, USA
    Drug Metab Dispos 30:694-700. 2002
    b>Raloxifene, a selective estrogen receptor modulator used for the treatment of osteoporosis, undergoes extensive conjugation to the 6-beta- and 4'-beta-glucuronides in vivo...
  25. ncbi Comparative effects of 17beta-estradiol, raloxifene and genistein on bone 3D microarchitecture and volumetric bone mineral density in the ovariectomized mice
    A Cano
    Department of Pediatrics, Obstetrics and Gynecology, University of Valencia, Valencia, Spain
    Osteoporos Int 19:793-800. 2008
    This study assessed the effect of estradiol, raloxifene and genistein on the preservation of bone 3D-microarchitecture and volumetric bone mineral density (vBMD) in the ovariectomized mouse model...
  26. pmc Treatment with selective estrogen receptor modulators regulates myelin specific T-cells and suppresses experimental autoimmune encephalomyelitis
    Bruce F Bebo
    Neurological Sciences Institute, Oregon Health and Science University, Beaverton, Oregon, USA
    Glia 57:777-90. 2009
    ..In this study, we investigated the ability of two commercially available SERMs (tamoxifen and raloxifene) to regulate myelin specific immunity and experimental autoimmune encephalomyelitis (EAE) in mice...
  27. ncbi From adjuvant therapy to breast cancer prevention: BCPT and STAR
    B K Dunn
    Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, USA
    Breast J 7:144-57. 2001
    ..b>Raloxifene, a second-generation SERM approved for the prevention of osteoporosis in postmenopausal women, displays ..
  28. ncbi Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis
    S Adami
    Riabilitazione Reumatologica, University of Verona, Valeggio s Mincio, Verona, Italy
    Osteoporos Int 19:87-94. 2008
    ..Sequential raloxifene prevented rapid bone loss at lumbar spine and further increased bone mineral density (BMD) at femoral neck, ..
  29. ncbi Raloxifene analog LY117018 enhances the regeneration of sciatic nerve in ovariectomized female mice
    R McMurray
    Department of Physiology, The Brody School of Medicine at East Carolina University, 600 Moye Blvd, Greenville, NC 27858, USA
    Brain Res 980:140-5. 2003
    ..Our study suggests that LY117018 may markedly accelerate peripheral nerve regeneration and functional recovery through activation of estrogen receptors...
  30. ncbi Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy
    F Cosman
    Clinical Research Center, Helen Hayes Hospital, West Haverstraw, NY 10993, USA
    Osteoporos Int 19:529-35. 2008
    Women with osteoporosis on raloxifene were randomized to 1-34hPTH + raloxifene or raloxifene alone for one year. In the PTH + raloxifene group, bone turnover increased 125-584%, spine BMD increased 9.6%, hip BMD increased 1.2-3...
  31. ncbi Raloxifene is not associated with biologically relevant changes in hot flushes in postmenopausal women for whom therapy is appropriate
    Santiago Palacios
    Instituto Palacios, Madrid, Spain
    Am J Obstet Gynecol 191:121-31. 2004
    b>Raloxifene is approved for the treatment and prevention of postmenopausal osteoporosis. Previous studies have described a raloxifene-associated increase in hot flushes, reported as adverse events...
  32. doi Incidence of invasive breast cancer in postmenopausal women after discontinuation of long-term raloxifene administration
    Victor G Vogel
    Department of Research, American Cancer Society, Atlanta, GA, USA
    Clin Breast Cancer 9:45-50. 2009
    ..women with osteoporosis had a 66% relative risk reduction for invasive breast cancer over 8 years of raloxifene therapy in the randomized, placebo-controlled 4-year MORE (Multiple Outcomes of Raloxifene Evaluation) trial and ..
  33. ncbi Transition from estrogen therapy to raloxifene in postmenopausal women: effects on treatment satisfaction and the endometrium-a pilot study
    Susan R Davis
    Jean Hailes Foundation, Melbourne, Australia
    Menopause 11:167-75. 2004
    To compare the effects of transferring from low-dose, transdermal estrogen to raloxifene with a phase of alternate-day raloxifene therapy with or without low-dose transdermal estrogen on patient satisfaction, endometrial changes, and ..
  34. ncbi Transition from estrogen-progestin to raloxifene in postmenopausal women: effect on vasomotor symptoms
    Stephen Gordon
    Women s Health and Internal Medicine, Comprehensive NeuroScience, Inc, 6065 Roswell, Suite 820, Atlanta, GA 30328, USA
    Obstet Gynecol 103:267-73. 2004
    To compare vasomotor symptoms after transition from estrogen-progestin therapy to raloxifene 60 mg/d with and without a placebo washout.
  35. ncbi Novel biodegradable polyesters. Synthesis and application as drug carriers for the preparation of raloxifene HCl loaded nanoparticles
    Dimitrios Bikiaris
    Laboratory of Organic Chemical Technology, Chemistry Department, Aristotle University of Thessaloniki, 541 24 Thessaloniki, Greece
    Molecules 14:2410-30. 2009
    b>Raloxifene HCl is a drug with poor bioavailability and poor water solubility. Furthermore nomicron pharmaceutically acceptable organic solvent has been reported before to dilute the drug...
  36. ncbi Effects of estrogen and raloxifene on neuroglia number and morphology in the hippocampus of aged female mice
    D L Lei
    Laboratory of Experimental Gerontology, Gerontology Research Center, National Institute on Aging, NIH, Baltimore, MD 21224, USA
    Neuroscience 121:659-66. 2003
    Hormone replacement therapy with the gonadal steroid estrogen or synthetic agents such as raloxifene, a selective estrogen receptor modulator, may affect cellular function in brains of postmenopausal women...
  37. ncbi Estrogen and raloxifene modulate leptin and its receptor in hypothalamus and adipose tissue from ovariectomized rats
    Rosaria Meli
    Department of Experimental Pharmacology, University of Naples, Italy
    Endocrinology 145:3115-21. 2004
    ..OVX) rats modification of estrogen levels or treatment with a selective estrogen receptor modulator, raloxifene (RAL), alters leptinemia and modulates leptin receptor (Ob-R) abundance in hypothalamus and white adipose tissue,..
  38. doi Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women
    Wen Ling Lee
    Division of Endocrinology and Metabolism, Department of Medicine, Chen Hsin Rehabilitation Center Taipei, Taiwan
    Maturitas 60:92-107. 2008
    ..Among these SERMs, raloxifene may be the most attractive agent based on the evidence from five recent large trials (Multiple Outcomes of ..
  39. pmc Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease
    Lori Mosca
    Director, Preventive Cardiology, New York Presbyterian Hospital, 601 West 168th Street, 43, New York, NY 10032, USA
    Stroke 40:147-55. 2009
    b>Raloxifene, a selective estrogen receptor modulator, reduces risk of invasive breast cancer and osteoporosis, but the effect on risk for stroke and venous thromboembolism in different patient subgroups is not established...
  40. ncbi Estradiol and raloxifene protect cultured SN4741 neurons against oxidative stress
    Eric Biewenga
    Biology Department, University of Colorado at Denver, P O Box 173364, Denver, CO 80217 3364, USA
    Neurosci Lett 373:179-83. 2005
    ..We used the clonal substantia nigra cell line SN4741 to compare the neuroprotective properties of estrogen and raloxifene against oxidative stress, and to determine whether raloxifene acted as an estrogen agonist or antagonist in this ..
  41. pmc Estrogen and raloxifene improve metaphyseal fracture healing in the early phase of osteoporosis. A new fracture-healing model at the tibia in rat
    E K Stuermer
    Department of Trauma Surgery, Plastic and Reconstructive Surgery, Georg August University of Goettingen, Robert Koch Str 40, 37099, Gottingen, Germany
    Langenbecks Arch Surg 395:163-72. 2010
    ..Quality and speed of fracture healing in osteoporotic fractures are crucial with regard to the outcome of patients. The question arises whether established antiosteoporotic drugs can further improve fracture healing...
  42. ncbi Biomedicine. Defining the "S" in SERMs
    Benita S Katzenellenbogen
    Department of Molecular and Integrative Physiology, University of Illinois and College of Medicine at Urbana Champaign, Urbana, IL 61801, USA
    Science 295:2380-1. 2002
  43. ncbi Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia
    Sarah E Lawrence
    Department of Pediatrics, University of Ottawa, Ontario, Canada
    J Pediatr 145:71-6. 2004
    ..To assess the efficacy of the anti-estrogens tamoxifen and raloxifen in the medical management of persistent pubertal gynecomastia...
  44. ncbi Raloxifene enhances vertebral mechanical properties independent of bone density
    Matthew R Allen
    Department of Anatomy and Cell Biology, MS 5035, Indiana University School of Medicine, 635 Barnhill Drive, Indianapolis, IN 46202, USA
    Bone 39:1130-5. 2006
    ..10 mg/kg/day), alendronate (ALN, 0.2 mg/kg/day), raloxifene (RAL, 0.50 mg/kg/day), or saline (VEH, 1 ml/kg/day)...
  45. pmc The NSABP Study of Tamoxifen and Raloxifene (STAR) trial
    Victor G Vogel
    University of Pittsburgh Cancer Institute, Magee Womens Hospital, Pittsburgh, PA 15213 3180, USA
    Expert Rev Anticancer Ther 9:51-60. 2009
    In the Study of Tamoxifen and Raloxifene (STAR) trial, postmenopausal women at increased risk of breast cancer received either oral tamoxifen (20 mg/day) or raloxifene (60 mg/day) over 5 years...
  46. ncbi Solid state interaction of raloxifene HCl with different hydrophilic carriers during co-grinding and its effect on dissolution rate
    Anuj Garg
    Department of Pharmaceutics, Institute of Technology, Banaras Hindu University, Varanasi, India
    Drug Dev Ind Pharm 35:455-70. 2009
    ..methyl cellulose and hydroxy propyl cellulose], and Sodium Alginate) on the solid state and dissolution rate of Raloxifene hydrochloride (R-HCl)...
  47. ncbi Increased thyroid-stimulating hormone levels associated with concomitant administration of levothyroxine and raloxifene
    Candice L Garwood
    Department of Pharmacy Practice, Wayne State University, Detroit, Michigan 48201, and the Department of Family Medicine, University of Iowa Hospitals and Clinics, Iowa City, USA
    Pharmacotherapy 26:881-5. 2006
    ..Her levothyroxine dosage of 0.05 mg/day had been stable for the past 15 months. She was then prescribed raloxifene for prevention of osteoporosis secondary to early menopause...
  48. ncbi Raloxifene exposure enhances brain activation during memory performance in healthy elderly males; its possible relevance to behavior
    R Goekoop
    Department of Neurology, VU University Medical Center, De Boelelaan 1117 1081 HV, Amsterdam, The Netherlands
    Neuroimage 25:63-75. 2005
    b>Raloxifene is a selective estrogen receptor modulator (SERM) that is prescribed in females only, but its use in male subjects is increasingly considered...
  49. ncbi Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis
    Marjorie Luckey
    St Barnabas Osteoporosis and Metabolic Bone Disease Center, Livingston, NJ, USA
    Menopause 11:405-15. 2004
    To compare the efficacy and tolerability of once-weekly (OW) alendronate (ALN) 70 mg and raloxifene (RLX) 60 mg daily in the treatment of postmenopausal osteoporosis.
  50. ncbi QUS in monitoring raloxifene and estrogen-progestogens: a 4-year longitudinal study
    D Agostinelli
    Presidio Ospedaliero di Terlizzi, Unita Operativa di Ginecologia e Ostetricia, Ambulatorio per la Menopausa, Terlizzi, Bari, Italy
    Ultrasound Med Biol 33:1184-90. 2007
    ..is to evaluate the effectiveness of phalangeal quantitative ultrasound (QUS) in monitoring the treatment with raloxifene or estrogen-progestogens in postmenopausal women attending an Italian Menopause Centre...
  51. pmc Return of chronic pelvic pain from endometriosis after raloxifene treatment: a randomized controlled trial
    Pamela Stratton
    Reproductive Biology and Medicine Branch, National Institutes of Health, Bethesda, Maryland, USA
    Obstet Gynecol 111:88-96. 2008
    To evaluate whether 6 months of raloxifene was effective in treatment of chronic pelvic pain in women with endometriosis.
  52. pmc Fractures in women treated with raloxifene or alendronate: a retrospective database analysis
    Shonda A Foster
    Eli Lilly and Company, Indianapolis, IN, USA
    BMC Womens Health 13:15. 2013
    b>Raloxifene and alendronate are anti-resorptive therapies approved for the prevention and treatment of postmenopausal osteoporosis...
  53. ncbi Effects of raloxifene therapy on circulating osteoprotegerin and RANK ligand levels in post-menopausal osteoporosis
    D Fernàndez-Garcia
    Bone Metabolic Unit, Endocrinology Division, University Hospital San Cecilio Granada, RETICEF, Granada, Spain
    J Endocrinol Invest 31:416-21. 2008
    Previous in vitro studies suggest that the anti-resorptive effect of raloxifene might be mediated by changes in several cytokines involved in the bone remodeling process...
  54. doi Effect of selective estrogen receptor modulator/raloxifene analogue on proliferation and collagen metabolism of tendon fibroblast
    Toru Irie
    Department of Orthopaedic Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Japan
    Connect Tissue Res 51:179-87. 2010
    The selective estrogen receptor modulator raloxifene is therapeutically beneficial for postmenopausal connective tissue degradation, such as osteoporosis, vascular sclerosis, and dermal degradation; however, the effects of raloxifene on ..
  55. doi Estrogen therapy for hereditary haemorrhagic telangiectasia (HHT): Effects of raloxifene, on Endoglin and ALK1 expression in endothelial cells
    Virginia Albiñana
    Centro de Investigaciones Biologicas, Spanish Research Council CSIC, Madrid, Spain
    Thromb Haemost 103:525-34. 2010
    ..We report preliminary results obtained with Raloxifene to treat epistaxis in postmenopausal HHT women diagnosed with osteoporosis...
  56. ncbi Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma no concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women
    A Saitta
    Department of Internal Medicine, Section of Pharmacology, University of Messina, Messina, Italy
    Arterioscler Thromb Vasc Biol 21:1512-9. 2001
    ..b>Raloxifene relaxes coronary arteries in vitro by an estrogen receptor-dependent and NO-dependent mechanism, thus suggesting ..
  57. doi Randomized, controlled study of the effects of raloxifene on high sensitivity C-reactive protein and serum lipids
    Efser Oztas
    Department of Obstetrics and Gynecology, Faculty of Medicine, Ufuk University, Ankara, Turkey
    Arch Gynecol Obstet 283:71-7. 2011
    To investigate the effects of raloxifene, on serum lipids and high-sensitivity C-reactive protein (hs-CRP) in healthy postmenopausal women.
  58. pmc Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene
    Seung Sang Ko
    Georgetown University Medical Center, Lombardi Comprehensive Cancer Center, Department of Oncology, 3970 Reservoir Rd N W, Washington, DC 20057, USA
    Expert Opin Pharmacother 12:657-74. 2011
    b>Raloxifene, a non-steroidal selective estrogen receptor modulator (SERM), offers a new dimension for the treatment and prevention of osteoporosis and risk reduction of invasive breast cancer in postmenopausal populations at high risk...
  59. doi In vitro evaluation, biodistribution in rats of radiolabeled raloxifene
    Elif Bayrak
    Ege University, Institute of Nuclear Science, Department of Nuclear Applications, Bornova, 35100 Izmir, Turkey
    Appl Radiat Isot 68:33-6. 2010
    b>Raloxifene is a selective estrogen receptor modulator that produces both estrogen agonistic effects on bone and lipid metabolism and estrogen-antagonistic effects on uterine endometrium and breast tissue...
  60. ncbi Post-menopausal women with rheumatoid arthritis who are treated with raloxifene or alendronate or glucocorticoids have lower serum undercarboxylated osteocalcin levels
    S Mokuda
    Department of Internal Medicine, Center for Rheumatic Diseases, Dohgo Spa Hospital, 21 21 Otsu Dohgo Himezuka, Matsuyama, Ehime, 790 0858, Japan
    J Endocrinol Invest 35:661-4. 2012
    ..It had been reported that bone resorption inhibitors tend to decrease the serum ucOC level in patients with primary osteoporosis. In rheumatoid arthritis (RA) patients, these results have never been reported...
  61. pmc Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials
    Matthew P Goetz
    Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Cancer Res 17:6944-51. 2011
    ..Controversy exists regarding the association between CYP2D6 enzyme activity and tamoxifen effectiveness in the adjuvant treatment of invasive breast cancer; however, this association in the primary prevention of breast cancer is unknown...
  62. doi Raloxifene reduces blood pressure in hypertensive animals after ovarian hormone deprivation
    Adriana Nunes Moraes
    Department of Health Sciences, CEUNES, Federal University of Espirito Santo, São Mateus, ES, Brazil
    Basic Clin Pharmacol Toxicol 109:334-8. 2011
    b>Raloxifene is a selective oestrogen receptor modulator that has been approved for the prevention and treatment of osteoporosis in post-menopausal women...
  63. pmc Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older
    Andrew N Freedman
    Division of Cancer Prevention, National Cancer Institute, 6130 Executive Blvd, Bethesda, MD 20892, USA
    J Clin Oncol 29:2327-33. 2011
    The Study of Tamoxifen and Raloxifene (STAR) demonstrated that raloxifene was as effective as tamoxifen in reducing the risk of invasive breast cancer (IBC) in postmenopausal women and had lower risks of thromboembolic events, endometrial ..
  64. ncbi Adiponectin and leptin serum levels in osteoporotic postmenopausal women treated with raloxifene or alendronate
    Arantzazu Sebastián-Ochoa
    Endocrinology Division, Hospital Universitario San Cecilio, Granada, Spain
    Menopause 19:172-7. 2012
    ..determine adiponectin and leptin levels in osteoporotic postmenopausal women and their relationship with bone mass and bone turnover and to analyze changes on adiponectin and leptin levels after treatment with raloxifene or alendronate.
  65. doi Raloxifene temporarily reduces arterial stiffness
    Satoshi Obayashi
    Department of Comprehensive Reproductive Medicine, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan
    J Obstet Gynaecol Res 36:1229-35. 2010
    ..The purpose of this paper was to evaluate the change of CAVI during one-year use of raloxifene (RLX).
  66. ncbi A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX
    John A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Beech Hill Road, Sheffield, UK
    Bone 47:729-35. 2010
    Multiple Outcomes of Raloxifene Evaluation (MORE), a placebo controlled phase III study of raloxifene in postmenopausal osteoporosis, showed that both doses tested (60 mg and 120 mg daily) reduced the risk of vertebral fracture...
  67. doi XbaI polymorphism of the estrogen receptor alpha gene influences the effect of raloxifene on the endothelial function
    Andrej Zavratnik
    Department of Endocrinology, University Medical Centre, Ljubljanska 5, 2000 Maribor, Slovenia
    Maturitas 67:84-90. 2010
    ..The selective estrogen receptor modulator, raloxifene, exerts a part of its actions through the estrogen receptor alpha (ESR1) activation...
  68. ncbi Randomized control study of the effects of raloxifene on serum lipids and homocysteine in older women
    V De Leo
    Department of Obstetrics and Gynecology, University of Siena, Italy
    Am J Obstet Gynecol 184:350-3. 2001
    b>Raloxifene, a selective estrogen receptor modulator, has beneficial estrogen agonist effects on bone and cardiovascular risk factors and estrogen antagonist effects on the breast and uterus...
  69. ncbi Transcriptional activities of estrogen receptor alpha and beta in yeast properties of raloxifene
    E Jisa
    Institute of Applied Microbiology, University of Agricultural Sciences, Vienna, Austria
    Biochem Pharmacol 62:953-61. 2001
    b>Raloxifene represents a potent compound for the prevention and treatment of osteoporosis and cardiovascular disease in postmenopausal women...
  70. ncbi Raloxifene improves vascular reactivity in pressurized septal coronary arteries of ovariectomized hamsters fed cholesterol diet
    Yau Chi Chan
    Institute of Vascular Medicine, Li Ka Shing Institute of Health Sciences, and School of Biomedical Sciences, Chinese University of Hong Kong, Hong Kong, China
    Pharmacol Res 65:182-8. 2012
    ..The impact of raloxifene therapy and cholesterol diet on myogenic constriction during estrogen deficiency is unresolved...
  71. ncbi Circulating chemoattractants RANTES, negatively related to endogenous androgens, and MCP-1 are differentially suppressed by hormone therapy and raloxifene
    George E Christodoulakos
    2nd Department of Obstetrics and Gynecology, University of Athens, Aretaieio Hospital, Athens, Greece
    Atherosclerosis 193:142-50. 2007
    ..Furthermore, the conflicting reports on the cardiovascular effects of hormone therapy between observational and clinical trials have triggered interest on the effect of alternative therapies on the cardiovascular system...
  72. ncbi Structural modulation of reactivity/activity in design of improved benzothiophene selective estrogen receptor modulators: induction of chemopreventive mechanisms
    Bolan Yu
    Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, 833 South Wood Street, Chicago, IL 60612, USA
    Mol Cancer Ther 6:2418-28. 2007
    The benzothiophene selective estrogen receptor modulators (SERM) raloxifene and arzoxifene are in clinical use and clinical trials for chemoprevention of breast cancer and other indications...
  73. doi Tamoxifen and raloxifene suppress the proliferation of estrogen receptor-negative cells through inhibition of glutamine uptake
    Valentina K Todorova
    Department of Surgery Breast Surgical Oncology, University of Arkansas for Medical Sciences, 4301W Markham St, Mail Slot 725, Little Rock, AR 72205, USA
    Cancer Chemother Pharmacol 67:285-91. 2011
    ..We hypothesized that one of the mechanisms responsible for ER-independent anti-neoplastic properties of SERMs and also for their adverse side effects could be dependent on the inhibition of Gln uptake...
  74. ncbi Estrogen and raloxifene induce apoptosis by activating p38 mitogen-activated protein kinase cascade in synthetic vascular smooth muscle cells
    A Mori-Abe
    Department of Obstetrics and Gynecology, Yamagata University, School of Medicine, 2 2 2 Iidanishi, Yamagata 990 9585, Japan
    J Endocrinol 178:417-26. 2003
    ..In addition, the effect of raloxifene on VSMC remains unknown...
  75. ncbi Raloxifene acts as an estrogen agonist on the rabbit growth plate
    Ola Nilsson
    Pediatric Endocrinology Unit, Department of Women and Child Health, Karolinska Institutet, SE 17176 Stockholm, Sweden
    Endocrinology 144:1481-5. 2003
    ..b>Raloxifene, a selective estrogen receptor modulator, has been shown to act as an estrogen agonist on bone density but as an ..
  76. ncbi Effects of raloxifene on platelet functions in patients with postmenopausal osteoporosis
    Derun Taner Ertugrul
    Faculty of Medicine, Department of Endocrinology and Metabolism, Baskent University, Ankara, Turkey
    Platelets 17:351-3. 2006
    Many studies have addressed the effects of estrogenic compounds on platelet function. Raloxifene is a selective estrogen receptor modulator (SERM), which is currently used for the treatment of postmenopausal osteoporosis...
  77. ncbi Effects of raloxifene treatment on uterine leiomyomas in postmenopausal women
    S Palomba
    Department of Obstetrics and Gynecology, University of Naples Federico II, Naples, Italy
    Fertil Steril 76:38-43. 2001
    To evaluate the effects of raloxifene administration on uterine and uterine leiomyoma sizes in postmenopausal women.
  78. doi Estrogen receptor ligands counteract cognitive deficits caused by androgen deprivation in male rats
    Natalia Lagunas
    Instituto Cajal, CSIC, E 28002 Madrid, Spain
    Horm Behav 59:581-4. 2011
    ..In addition, we tested the effect of raloxifene and tamoxifen, two selective estrogen receptor modulators used in clinical practice...
  79. pmc Comparative methods for analysis of protein covalent modification by electrophilic quinoids formed from xenobiotics
    Bolan Yu
    Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, 60612, USA
    Bioconjug Chem 20:728-41. 2009
    ..For study of the protein targets of electrophilic metabolites formed by in situ oxidative bioactivation, the COATag is both sensitive and specific and does not appear to suffer from poor cell permeability...
  80. doi The effects of long-term raloxifene and estradiol treatments on bone in a patient with congenital aromatase deficiency
    L Zirilli
    Integrated Department of Medicine, Endocrinology, Metabolism, and Geriatrics, University of Modena and Reggio Emilia, Via Giardini 1355, 41100 Modena, Italy
    Bone 45:827-32. 2009
    ..b>Raloxifene is a SERM with proven estrogen agonist action on bone that leads to an improvement in BMD and a reduction in ..
  81. ncbi Anti-inflammatory effect of selective estrogen receptor modulators (SERMs) in microglial cells
    T Suuronen
    Department of Neuroscience and Neurology, University of Kuopio, PO Box 1627, 70211 Kuopio, Finland
    Inflamm Res 54:194-203. 2005
    ..Our aim was to study how different SERMs modulate the inflammatory responses induced by lipopolysaccharide (LPS) or unmethylated CpG-oligonucleotides in mouse and rat microglial cells...
  82. ncbi Effects of raloxifene, a selective estrogen receptor modulator, on bone turnover markers and serum sex steroid and lipid levels in elderly men
    P M Doran
    Endocrine Research Unit, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    J Bone Miner Res 16:2118-25. 2001
    ..years), we performed a randomized blinded study to assess the effect of 6 months of treatment with 60 mg/day of raloxifene (a selective estrogen receptor modulator [SERM] that has an agonist effect on bone but is not feminizing) versus ..
  83. doi Estrogen receptor-beta as a potential target for colon cancer prevention: chemoprevention of azoxymethane-induced colon carcinogenesis by raloxifene in F344 rats
    Naveena B Janakiram
    Department of Medicine, Hem Onc Section, OU Cancer Institute, University of Oklahoma Health Sciences Center, 975 Northeast 10th Street, Oklahoma City, OK 73104, USA
    Cancer Prev Res (Phila) 2:52-9. 2009
    b>Raloxifene, selective estrogen receptor (ER) modulator, is not fully explored in colorectal cancer...
  84. pmc Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case-control study
    Angela DeMichele
    Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, USA
    J Clin Oncol 26:4151-9. 2008
    b>Raloxifene reduces breast cancer risk in women with osteoporosis, and both tamoxifen and raloxifene prevent breast cancer in high-risk women...
  85. ncbi Both estrogen and raloxifene protect against beta-amyloid-induced neurotoxicity in estrogen receptor alpha-transfected PC12 cells by activation of telomerase activity via Akt cascade
    Botao Du
    Department of Obstetrics and Gynecology, Yamagata University, School of Medicine, 2 2 2 Iidanishi, Yamagata 990 9585, Japan
    J Endocrinol 183:605-15. 2004
    ..In addition, the effect of raloxifene on Abeta-induced neuro-toxicity remains unknown...
  86. pmc Uterine peroxidase-catalyzed formation of diquinone methides from the selective estrogen receptor modulators raloxifene and desmethylated arzoxifene
    Hong Liu
    Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, 833 South Wood Street, M C 781, Chicago, Illinois 60612 7231, USA
    Chem Res Toxicol 20:1676-84. 2007
    ..We have previously shown that the benzothiophene SERMs, raloxifene and desmethylated arzoxifene (DMA), can also be bioactivated to electrophilic quinoids by rat/human liver ..
  87. ncbi Raloxifene inhibits matrix metalloproteinases expression and activity in macrophages and smooth muscle cells
    Stefano Bellosta
    Department of Pharmacological Sciences, University of Milan, Via Balzaretti 9, 20133 Milan, Italy
    Pharmacol Res 56:160-7. 2007
    ..We investigated the effects of raloxifene, a second generation SERM, on MMP expression and activity in cultured macrophages and SMC, and in rabbit carotid ..
  88. ncbi Raloxifene inhibits estrogen-induced up-regulation of telomerase activity in a human breast cancer cell line
    Jun Kawagoe
    Department of Obstetrics and Gynecology, Yamagata University, School of Medicine, Iidanishi, Yamagata, Japan
    J Biol Chem 278:43363-72. 2003
    The mechanism by which raloxifene acts in the chemoprevention of breast cancer remains unclear...
  89. ncbi Does raloxifene treatment influence back pain and disability among postmenopausal women with osteoporosis?
    Georgios Papadokostakis
    Department of Orthopaedic Surgery and Traumatology, University General Hospital, Heraklio, Crete, Greece
    Eur Spine J 14:977-81. 2005
    ..b>Raloxifene, a selective estrogen receptor modulator has estrogen-like effects on bone tissue, and antagonize the action of ..
  90. ncbi Raloxifene prevents endothelial dysfunction in aging ovariectomized female rats
    Chi Ming Wong
    Li Ka Shing Institute of Health Sciences, Chinese University of Hong Kong, Hong Kong, China
    Vascul Pharmacol 44:290-8. 2006
    ..in vascular reactivity in the aging (15 months old) female rat after ovariectomy and the effects of chronic raloxifene therapy on vascular reactivity and eNOS protein expression...
  91. pmc Analysis of protein covalent modification by xenobiotics using a covert oxidatively activated tag: raloxifene proof-of-principle study
    Ju Liu
    Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, 833 South Wood Street, M C 781, Chicago, Illinois 60612, USA
    Chem Res Toxicol 18:1485-96. 2005
    ..b>Raloxifene, in common with many SERMs and other xenobiotics, is a polyaromatic phenol that has been shown to be ..
  92. ncbi Skeletal pain in postmenopausal women with osteoporosis: prevalence and course during raloxifene treatment in a prospective observational study of 6 months duration
    S Scharla
    Practice for Internal Medicine and Endocrinology, Bad Reichenhall, Germany
    Curr Med Res Opin 22:2393-402. 2006
    To assess the prevalence of skeletal pain in postmenopausal women before the onset of raloxifene treatment and the further course of pain during treatment in a naturalistic setting.
  93. doi The selective estrogen receptor modulator raloxifene inhibits cardiac delayed rectifier potassium currents and voltage-gated sodium current without QTc interval prolongation
    Hui Liu
    Department of Pharmacology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
    Pharmacol Res 62:384-90. 2010
    b>Raloxifene is widely used in the treatment of postmenopausal osteoporosis and also has been shown to be cardioprotective. The effect of raloxifene on cardiac ion channels is not fully understood...
  94. ncbi Effects of ovarian steroids and raloxifene on proteins that synthesize, transport, and degrade serotonin in the raphe region of macaques
    Lisa J Smith
    Division of Reproductive Sciences, Oregon National Primate Research Center, Beaverton, OR, USA
    Neuropsychopharmacology 29:2035-45. 2004
    ..questioned what effect would 1 or 5 mo of ovarian hormones or the selective estrogen receptor modulator (SERM), raloxifene, have on TPH protein and phosphorylation, and on protein expression of SERT, MAO-A or MAO-B? Raloxifene ..
  95. doi Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene
    P Vestergaard
    Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark
    Osteoporos Int 22:993-1001. 2011
    ..This may suggest an effect of the underlying disease rather than the drugs used...
  96. ncbi Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study
    Fredrik Borgstrom
    Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden
    Pharmacoeconomics 22:1153-65. 2004
    The Multiple Outcomes of Raloxifene Evaluation (MORE) study showed that treatment with raloxifene reduces the risk of vertebral fracture and breast cancer in postmenopausal women with osteoporosis.
  97. ncbi Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials
    F J Cohen
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Maturitas 34:65-73. 2000
    b>Raloxifene, a selective estrogen receptor modulator, is estrogen-like in the skeleton and cardiovascular system and antiestrogenic in reproductive tissues...
  98. ncbi Vascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial: incidence, patient characteristics, and effect of raloxifene
    Claire S Duvernoy
    VA Medical Center, University of Michigan Department of Internal Medicine, Division of Cardiology, Ann Arbor, MI 48105, USA
    Menopause 12:444-52. 2005
    To determine the incidence of arterial and venous thromboembolic (VTE) events, to determine the effect of raloxifene on the incidence of combined vascular (arterial and VTE) events, and to identify patient characteristics associated with ..
  99. ncbi Effects of calcitonin, risedronate, and raloxifene on erythrocyte antioxidant enzyme activity, lipid peroxidation, and nitric oxide in postmenopausal osteoporosis
    Salih Ozgocmen
    Division of Rheumatology, Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Firat University, Elazig, Turkey
    Arch Med Res 38:196-205. 2007
    ..Additionally, in vivo effects of three different anti-osteoporotic drugs, calcitonin, risedronate and raloxifene, on the erythrocyte oxidant-antioxidant status in women with PMO were also assessed.
  100. pmc Raloxifene inhibits tumor growth and lymph node metastasis in a xenograft model of metastatic mammary cancer
    Masa Aki Shibata
    Department of Anatomy and Cell Biology, Division of Life Sciences, Osaka Medical College, 2 7 Daigaku machi, Takatsuki, Osaka 569 8686, Japan
    BMC Cancer 10:566. 2010
    The effects of raloxifene, a novel selective estrogen receptor modulator, were studied in a mouse metastatic mammary cancer model expressing cytoplasmic ERα.
  101. ncbi Effects of raloxifene therapy on the anticoagulant system in postmenopausal women
    G D Azevedo
    Department of Obstetrics and Gynecology, Faculty of Medicine of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto SP, Brazil
    Climacteric 6:140-5. 2003
    b>Raloxifene therapy is associated with a three-fold increase in the risk for venous thromboembolism; however, its effects on the hemostatic system in postmenopausal women have not been well defined.

Research Grants71

  1. Effects of herbs on transcription and cell proliferation
    Dale Leitman; Fiscal Year: 2002
    ..recently, SERMs are becoming increasingly popular for preventing cancer, since studies found that tamoxifen and raloxifene reduce the incidence of estrogen receptor positive breast tumors...
  2. Effects of herbs on transcription and cell proliferation
    Dale Leitman; Fiscal Year: 2003
    ..recently, SERMs are becoming increasingly popular for preventing cancer, since studies found that tamoxifen and raloxifene reduce the incidence of estrogen receptor positive breast tumors...
  3. IMMUNOLOGICAL ASPECTS OF HEMORRHAGE
    Irshad Chaudry; Fiscal Year: 2000
    ..We will evaluate if administration of beta-estradiol, Raloxifene or PRL in vivo after trauma-hemorrhage improves the depressed immune responses in estrogen deficient mice...
  4. IMMUNOLOGICAL ASPECTS OF HEMORRHAGE
    Irshad Chaudry; Fiscal Year: 1999
    ..We will evaluate if administration of beta-estradiol, Raloxifene or PRL in vivo after trauma-hemorrhage improves the depressed immune responses in estrogen deficient mice...
  5. IMMUNOLOGICAL ASPECTS OF HEMORRHAGE
    Irshad Chaudry; Fiscal Year: 2002
    ..We will evaluate if administration of beta-estradiol, Raloxifene or PRL in vivo after trauma-hemorrhage improves the depressed immune responses in estrogen deficient mice...
  6. IMMUNOLOGICAL ASPECTS OF HEMORRHAGE
    Irshad Chaudry; Fiscal Year: 2001
    ..We will evaluate if administration of beta-estradiol, Raloxifene or PRL in vivo after trauma-hemorrhage improves the depressed immune responses in estrogen deficient mice...
  7. IMMUNOLOGICAL ASPECTS OF HEMORRHAGE
    Irshad Chaudry; Fiscal Year: 2000
    ..We will evaluate if administration of beta-estradiol, Raloxifene or PRL in vivo after trauma-hemorrhage improves the depressed immune responses in estrogen deficient mice...
  8. IMMUNOLOGICAL ASPECTS OF HEMORRHAGE
    Irshad Chaudry; Fiscal Year: 2002
    ..We will evaluate if administration of beta-estradiol, Raloxifene or PRL in vivo after trauma-hemorrhage improves the depressed immune responses in estrogen deficient mice...
  9. CARDIAC ESTROGEN RECEPTORS AND MI-- MOUSE MODELS
    Richard Karas; Fiscal Year: 2001
    ..of the role of estrogen receptors an the effect of estrogen receptor modulators, including the SERM raloxifene, on left ventricular remodeling following myocardial infarction, using wild-type, ERalphaKO and ERbetaKO mice, ..
  10. CARDIAC ESTROGEN RECEPTORS AND MI-- MOUSE MODELS
    Richard Karas; Fiscal Year: 2002
    ..of the role of estrogen receptors an the effect of estrogen receptor modulators, including the SERM raloxifene, on left ventricular remodeling following myocardial infarction, using wild-type, ERalphaKO and ERbetaKO mice, ..
  11. CARDIAC ESTROGEN RECEPTORS AND MI-- MOUSE MODELS
    Richard Karas; Fiscal Year: 2000
    ..of the role of estrogen receptors an the effect of estrogen receptor modulators, including the SERM raloxifene, on left ventricular remodeling following myocardial infarction, using wild-type, ERalphaKO and ERbetaKO mice, ..
  12. CARDIAC ESTROGEN RECEPTORS AND MI-- MOUSE MODELS
    Richard Karas; Fiscal Year: 2004
    ..of the role of estrogen receptors an the effect of estrogen receptor modulators, including the SERM raloxifene, on left ventricular remodeling following myocardial infarction, using wild-type, ERalphaKO and ERbetaKO mice, ..
  13. CARDIAC ESTROGEN RECEPTORS AND MI-- MOUSE MODELS
    Richard Karas; Fiscal Year: 2003
    ..of the role of estrogen receptors an the effect of estrogen receptor modulators, including the SERM raloxifene, on left ventricular remodeling following myocardial infarction, using wild-type, ERalphaKO and ERbetaKO mice, ..
  14. Female Hormones and Vision
    Alvin Eisner; Fiscal Year: 2005
    ..and visual system as a result of estrogen-receptor action and to elucidate the effects of 2 SERMS, tamoxifen and raloxifene, as functions of their durations of use...
  15. Female Hormones and Vision
    Alvin Eisner; Fiscal Year: 2004
    ..and visual system as a result of estrogen-receptor action and to elucidate the effects of 2 SERMS, tamoxifen and raloxifene, as functions of their durations of use...
  16. Female Hormones and Vision
    Alvin Eisner; Fiscal Year: 2006
    ..and visual system as a result of estrogen-receptor action and to elucidate the effects of 2 SERMS, tamoxifen and raloxifene, as functions of their durations of use...
  17. Female Hormones and Vision
    Alvin Eisner; Fiscal Year: 2003
    ..and visual system as a result of estrogen-receptor action and to elucidate the effects of 2 SERMS, tamoxifen and raloxifene, as functions of their durations of use...
  18. Estrogen Dependency of Uterine Leiomyoma
    Ayman Al Hendy; Fiscal Year: 2005
    ..g., tamoxifen and raloxifene) can significantly reduce tumor incidence, size, and proliferative index in the Eker rat, the only animal model ..
  19. Estrogen Dependency of Uterine Leiomyoma
    Ayman Al Hendy; Fiscal Year: 2007
    ..g., tamoxifen and raloxifene) can significantly reduce tumor incidence, size, and proliferative index in the Eker rat, the only animal model ..
  20. Estrogen Dependency of Uterine Leiomyoma
    Ayman Al Hendy; Fiscal Year: 2004
    ..g., tamoxifen and raloxifene) can significantly reduce tumor incidence, size, and proliferative index in the Eker rat, the only animal model ..
  21. Estrogen Dependency of Uterine Leiomyoma
    Ayman Al Hendy; Fiscal Year: 2003
    ..g., tamoxifen and raloxifene) can significantly reduce tumor incidence, size, and proliferative index in the Eker rat, the only animal model ..
  22. Estrogen Dependency of Uterine Leiomyoma
    Ayman Al Hendy; Fiscal Year: 2005
    ..g., tamoxifen and raloxifene) can significantly reduce tumor incidence, size, and proliferative index in the Eker rat, the only animal model ..
  23. Estrogen Dependency of Uterine Leiomyoma
    Ayman Al Hendy; Fiscal Year: 2007
    ..g., tamoxifen and raloxifene) can significantly reduce tumor incidence, size, and proliferative index in the Eker rat, the only animal model ..
  24. Estrogen Dependency of Uterine Leiomyoma
    Ayman Al Hendy; Fiscal Year: 2006
    ..g., tamoxifen and raloxifene) can significantly reduce tumor incidence, size, and proliferative index in the Eker rat, the only animal model ..
  25. Theranostic Nanomedicine for Breast Cancer Prevention and Image-Guided Therapy
    Prakash R Rai; Fiscal Year: 2010
    ..The strategy is to use Chemopreventive Nanocells (CPNC) that encapsulate raloxifene, anastrazole, metformin, fenretinide and celecoxib as preventive agents with indocyanine green (ICG) as the ..
  26. Hormones and Female Urinary Incontinence
    Tom Lue; Fiscal Year: 2005
    ..This will be accomplished by treating our established incontinence rat model with estrogen, progesterone, raloxifene, levormeloxifene, and growth hormone, followed by cystometrical analysis. Specific Aim 2...
  27. Hormones and Female Urinary Incontinence
    Tom Lue; Fiscal Year: 2007
    ..This will be accomplished by treating our established incontinence rat model with estrogen, progesterone, raloxifene, levormeloxifene, and growth hormone, followed by cystometrical analysis. Specific Aim 2...
  28. Hormones and Female Urinary Incontinence
    Tom Lue; Fiscal Year: 2006
    ..This will be accomplished by treating our established incontinence rat model with estrogen, progesterone, raloxifene, levormeloxifene, and growth hormone, followed by cystometrical analysis. Specific Aim 2...
  29. Hormones and Female Urinary Incontinence
    Tom Lue; Fiscal Year: 2009
    ..This will be accomplished by treating our established incontinence rat model with estrogen, progesterone, raloxifene, levormeloxifene, and growth hormone, followed by cystometrical analysis. Specific Aim 2...
  30. Theranostic Nanomedicine for Breast Cancer Prevention and Image-Guided Therapy
    Prakash R Rai; Fiscal Year: 2012
    ..The strategy is to use Chemopreventive Nanocells (CPNC) that encapsulate raloxifene, anastrazole, metformin, fenretinide and celecoxib as preventive agents with indocyanine green (ICG) as the ..
  31. A Molecular Basis for Phytoestrogen Chemoprevention
    Andrew Mesecar; Fiscal Year: 2002
    ..the only phytoestrogen-ER structure solved to date, to those of estradiol (agonist) bound to ER-alpha and Raloxifene (antagonist) bound to ER- beta, reveals that the phytoestrogen genistein induces a novel conformation in ER...
  32. A Molecular Basis for Phytoestrogen Chemoprevention
    Andrew Mesecar; Fiscal Year: 2001
    ..the only phytoestrogen-ER structure solved to date, to those of estradiol (agonist) bound to ER-alpha and Raloxifene (antagonist) bound to ER- beta, reveals that the phytoestrogen genistein induces a novel conformation in ER...
  33. SPECIALIZED CENTER OF RESEARCH IN ISCHEMIC HEART DISEASE
    Michael Mendelsohn; Fiscal Year: 2001
    ..Infarction", a secondary prevention trial at New England Medical Center with the selective ER modulator raloxifene; Project 3: "Cardiac ER and MI: Mouse Models", studies of ventricular remodeling, arrhythmogenic changes, and ..
  34. Interactions between SERMs, soy and black cohosh
    Heather Shaw; Fiscal Year: 2006
    ..b>Raloxifene, a newer SERM, is currently widely used for treatment of osteoporosis and is in trials for breast cancer ..
  35. Interactions between SERMs, soy and black cohosh
    Heather Shaw; Fiscal Year: 2005
    ..b>Raloxifene, a newer SERM, is currently widely used for treatment of osteoporosis and is in trials for breast cancer ..
  36. Interactions between SERMs, soy and black cohosh
    Heather Shaw; Fiscal Year: 2003
    ..b>Raloxifene, a newer SERM, is currently widely used for treatment of osteoporosis and is in trials for breast cancer ..
  37. MODEL FOR PELVIC FLOOR DISORDERS
    Amanda Clark; Fiscal Year: 2004
    ..Special attention will be paid to the effects of a SERM (raloxifene) as there are tow reports that experimental SERMs increase the incidence of POP...
  38. MODEL FOR PELVIC FLOOR DISORDERS
    Amanda Clark; Fiscal Year: 2000
    ..Special attention will be paid to the effects of a SERM (raloxifene) as there are tow reports that experimental SERMs increase the incidence of POP...
  39. Interactions between SERMs, soy and black cohosh
    Heather Shaw; Fiscal Year: 2007
    ..b>Raloxifene, a newer SERM, is currently widely used for treatment of osteoporosis and is in trials for breast cancer ..
  40. Interactions between SERMs, soy and black cohosh
    Heather Shaw; Fiscal Year: 2004
    ..b>Raloxifene, a newer SERM, is currently widely used for treatment of osteoporosis and is in trials for breast cancer ..
  41. MODEL FOR PELVIC FLOOR DISORDERS
    Amanda Clark; Fiscal Year: 2003
    ..Special attention will be paid to the effects of a SERM (raloxifene) as there are tow reports that experimental SERMs increase the incidence of POP...
  42. MODEL FOR PELVIC FLOOR DISORDERS
    Amanda Clark; Fiscal Year: 2002
    ..Special attention will be paid to the effects of a SERM (raloxifene) as there are tow reports that experimental SERMs increase the incidence of POP...
  43. MODEL FOR PELVIC FLOOR DISORDERS
    Amanda Clark; Fiscal Year: 2001
    ..Special attention will be paid to the effects of a SERM (raloxifene) as there are tow reports that experimental SERMs increase the incidence of POP...
  44. Antiestrogen Regulation of Bladder Cancer
    Carolyn Smith; Fiscal Year: 2009
    ..is expressed in multiple bladder cancer cell lines tested;3) the selective estrogen receptor modulators (SERMs), raloxifene and tamoxifen, inhibit growth of bladder cancer cell lines in vitro and 4) raloxifene and 4- hydroxytamoxifen ..
  45. Actions of Endoxifen on the Skeleton
    Anne Gingery; Fiscal Year: 2012
    ..Present day therapies involve anti-resorptive agents such as bisphosphonates, estrogen analogs, raloxifene and calcitonin which primarily target bone resorbing osteoclasts resulting in reduced bone turnover...
  46. REGULATION OF ESTROGEN-RESPONSIVE GENES
    ANN NARDULLI; Fiscal Year: 2004
    ..and coregutatory proteins involved in mediating the effects of estrogen and the SERMs 4-hydroxytamoxifen and raloxifene will be determined using in vivo footprinting and chromatin immunoprecipitation experiments...
  47. REGULATION OF ESTROGEN-RESPONSIVE GENES
    ANN NARDULLI; Fiscal Year: 2007
    ..and coregutatory proteins involved in mediating the effects of estrogen and the SERMs 4-hydroxytamoxifen and raloxifene will be determined using in vivo footprinting and chromatin immunoprecipitation experiments...
  48. REGULATION OF ESTROGEN-RESPONSIVE GENES
    ANN NARDULLI; Fiscal Year: 2006
    ..and coregutatory proteins involved in mediating the effects of estrogen and the SERMs 4-hydroxytamoxifen and raloxifene will be determined using in vivo footprinting and chromatin immunoprecipitation experiments...
  49. REGULATION OF ESTROGEN-RESPONSIVE GENES
    ANN NARDULLI; Fiscal Year: 2005
    ..and coregutatory proteins involved in mediating the effects of estrogen and the SERMs 4-hydroxytamoxifen and raloxifene will be determined using in vivo footprinting and chromatin immunoprecipitation experiments...
  50. Estrogen receptors in benign prostatic hyperplasia
    TRISTAN MARRINER NICHOLSON; Fiscal Year: 2012
    ..estrogen receptor modulators (SERMs) that target relevant ER subtypes and the clinically relevant SERMs Raloxifene and Fulvestrant...
  51. Hormone Replacement Therapy, SERMs & Leg Blood Flow in Postmenopausal Women
    DOUGLAS SEALS; Fiscal Year: 2007
    ..the present proposal is that HRT (transdermal estradiol) and/or a selective estrogen receptor modulator (SERM; raloxifene) will increase LBF in healthy previously estrogen deficient postmenopausal women by increasing LVC, with or ..
  52. PSYCHOBIOLOGY OF ESTROGEN RECEPTOR MODULATORS
    Mark Wilson; Fiscal Year: 2003
    ..This project will determine if the SERMs, tamoxifen and raloxifene, are E2 agonists or antagonists in the neuroendocrine regulation of behavior in female rhesus monkeys...
  53. PSYCHOBIOLOGY OF ESTROGEN RECEPTOR MODULATORS
    Mark Wilson; Fiscal Year: 2000
    ..This project will determine if the SERMs, tamoxifen and raloxifene, are E2 agonists or antagonists in the neuroendocrine regulation of behavior in female rhesus monkeys...
  54. PSYCHOBIOLOGY OF ESTROGEN RECEPTOR MODULATORS
    Mark Wilson; Fiscal Year: 2002
    ..This project will determine if the SERMs, tamoxifen and raloxifene, are E2 agonists or antagonists in the neuroendocrine regulation of behavior in female rhesus monkeys...
  55. PSYCHOBIOLOGY OF ESTROGEN RECEPTOR MODULATORS
    Mark Wilson; Fiscal Year: 2001
    ..This project will determine if the SERMs, tamoxifen and raloxifene, are E2 agonists or antagonists in the neuroendocrine regulation of behavior in female rhesus monkeys...
  56. HRT, SERMs and LEG BLOOD FLOW IN POSTMENOPAUSAL WOMEN
    DOUGLAS SEALS; Fiscal Year: 2006
    ..the present proposal is that HRT (transdermal estradiol) and/or a selective estrogen receptor modulator (SERM; raloxifene) will increase LBF in healthy previously estrogen deficient postmenopausal women by increasing LVC, with or ..
  57. HRT, SERMs and LEG BLOOD FLOW IN POSTMENOPAUSAL WOMEN
    DOUGLAS SEALS; Fiscal Year: 2004
    ..the present proposal is that HRT (transdermal estradiol) and/or a selective estrogen receptor modulator (SERM; raloxifene) will increase LBF in healthy previously estrogen deficient postmenopausal women by increasing LVC, with or ..
  58. HRT, SERMs and LEG BLOOD FLOW IN POSTMENOPAUSAL WOMEN
    DOUGLAS SEALS; Fiscal Year: 2005
    ..the present proposal is that HRT (transdermal estradiol) and/or a selective estrogen receptor modulator (SERM; raloxifene) will increase LBF in healthy previously estrogen deficient postmenopausal women by increasing LVC, with or ..
  59. Herb-Drug Glucuronidation Interactions
    Reginald F Frye; Fiscal Year: 2010
    ..on mycophenolic acid pharmacokinetics;and 2) the effect of green tea leaf extract administration on raloxifene pharmacokinetics...
  60. Prophylactic, risk-reducing surgery in BRCA-positive women: sexual functioning a
    Sharon Tollin; Fiscal Year: 2010
    ..Chemoprevention with tamoxifen or raloxifene is another risk-reducing option...
  61. Interferon and Raloxifene Effects on Cancer Cells
    CHERYL ROSENFELD; Fiscal Year: 2006
    ..The University is in the process of developing a Comparative Oncology Program. The campus provides a rich mix of disciplines and a collaborative environment, in which Dr. Rosenfeld is expected to continue to thrive. ..
  62. Interferon and Raloxifene Effects on Cancer Cells
    CHERYL ROSENFELD; Fiscal Year: 2007
    ..The University is in the process of developing a Comparative Oncology Program. The campus provides a rich mix of disciplines and a collaborative environment, in which Dr. Rosenfeld is expected to continue to thrive. ..
  63. Interferon and Raloxifene Effects on Cancer Cells
    CHERYL ROSENFELD; Fiscal Year: 2004
    ..The University is in the process of developing a Comparative Oncology Program. The campus provides a rich mix of disciplines and a collaborative environment, in which Dr. Rosenfeld is expected to continue to thrive. ..
  64. Interferon and Raloxifene Effects on Cancer Cells
    CHERYL ROSENFELD; Fiscal Year: 2003
    ..The University is in the process of developing a Comparative Oncology Program. The campus provides a rich mix of disciplines and a collaborative environment, in which Dr. Rosenfeld is expected to continue to thrive. ..
  65. Interferon and Raloxifene Effects on Cancer Cells
    CHERYL ROSENFELD; Fiscal Year: 2005
    ..The University is in the process of developing a Comparative Oncology Program. The campus provides a rich mix of disciplines and a collaborative environment, in which Dr. Rosenfeld is expected to continue to thrive. ..
  66. SPECIALIZED CENTER OF RESEARCH IN ISCHEMIC HEART DISEASE
    Michael Mendelsohn; Fiscal Year: 2000
    ..Infarction", a secondary prevention trial at New England Medical Center with the selective ER modulator raloxifene; Project 3: "Cardiac ER and MI: Mouse Models", studies of ventricular remodeling, arrhythmogenic changes, and ..
  67. SPECIALIZED CENTER OF RESEARCH IN ISCHEMIC HEART DISEASE
    Michael Mendelsohn; Fiscal Year: 2004
    ..Infarction", a secondary prevention trial at New England Medical Center with the selective ER modulator raloxifene; Project 3: "Cardiac ER and MI: Mouse Models", studies of ventricular remodeling, arrhythmogenic changes, and ..
  68. COGNITIVE AGING: EFFECTS OF ESTRADIOL AND RALOXIFENE
    AGNES LACREUSE; Fiscal Year: 2000
    ..We will use a rhesus monkey model of human menopause to examine the effects of estradiol and the SERM raloxifene on female cognition...
  69. SPECIALIZED CENTER OF RESEARCH IN ISCHEMIC HEART DISEASE
    Michael Mendelsohn; Fiscal Year: 2002
    ..Infarction", a secondary prevention trial at New England Medical Center with the selective ER modulator raloxifene; Project 3: "Cardiac ER and MI: Mouse Models", studies of ventricular remodeling, arrhythmogenic changes, and ..
  70. SPECIALIZED CENTER OF RESEARCH IN ISCHEMIC HEART DISEASE
    Michael Mendelsohn; Fiscal Year: 2003
    ..Infarction", a secondary prevention trial at New England Medical Center with the selective ER modulator raloxifene; Project 3: "Cardiac ER and MI: Mouse Models", studies of ventricular remodeling, arrhythmogenic changes, and ..
  71. ESTRADIOL & SERMS ON THE HYPOTHALAMIC/PITUITARY AXIS
    Lothar Jennes; Fiscal Year: 2000
    ..The development of Selective Estrogen Receptor Modulators (SERMs), such as Raloxifene that act either as an estradiol agonist or antagonist, depending upon the target cell was a major breakthrough ..